Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus

Gastroenterology. 2019 Feb;156(3):529-533.e4. doi: 10.1053/j.gastro.2018.11.062. Epub 2018 Dec 4.

Authors

Ryan Taylor Anderson¹, Seng Gee Lim², Poonam Mishra³, Filip Josephson⁴, Eric Donaldson³, Bruce Given⁵, Veronica Miller¹

Affiliations

¹ University of California, Berkeley, Washington, DC.
² National University of Singapore, Singapore, Republic of Singapore.
³ US Food and Drug Administration, Silver Spring, Maryland.
⁴ Swedish Medical Products Agency, Uppsala, Sweden.
⁵ Arrowhead Pharmaceuticals, Inc., Pasadena, California.

PMID: 30529300
DOI: 10.1053/j.gastro.2018.11.062

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Review

MeSH terms

Antiviral Agents / therapeutic use*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Disease Progression
Drug Therapy, Combination
Female
Hepatitis B, Chronic / diagnosis*
Hepatitis B, Chronic / drug therapy*
Humans
Liver Cirrhosis / prevention & control*
Liver Cirrhosis / virology
Male
Practice Guidelines as Topic
Risk Assessment
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Antiviral Agents